Phillips-Medisize, Dance Biopharm ink deal for inhaled insulin device

Share

Phillips-MedisizePrivately-held biotech Dance Biopharm and Phillips-Medisize have entered into a joint development deal for a connected drug-delivery device for inhaled insulin.

The agreement gives Phillips-Medisize, which already designs and manufactures devices for Dance, the development work for future enhancements of Dance’s devices, as well as commercial manufacturing of the inhaled insulin delivery device when it gets to the market.

The Dance 501 device stores a liquid formulation of recombinant human insulin in a dispenser with a hand-held electronic inhaler. The device uses vibrating mesh to produce particles of liquid insulin in a soft mist.

Get the full story on our sister site Drug Delivery Business News.

Want to stay on top of MDO content? Subscribe to our e-newsletter.

Speak Your Mind

*